TARA Profile
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and rare diseases. The company is focused on advancing its research pipeline with transformative treatments aimed at addressing unmet medical needs.
Protara's lead program, TARA-002, is an investigational cell therapy designed to treat lymphatic malformations. This therapy represents a significant advancement in the field, targeting complex conditions that have limited treatment options. The company is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy aimed at managing intestinal failure-associated liver disease. This product is intended to offer new hope for patients suffering from severe liver conditions related to their intestinal failure.
In addition to its primary programs, Protara is committed to leveraging its expertise in cell and gene therapy to explore further innovative treatment avenues. The company’s approach combines cutting-edge science with a strategic focus on high-need areas, positioning it at the forefront of biopharmaceutical innovation.
Founded as ArTara Therapeutics, Inc. in 2010, Protara Therapeutics, Inc. rebranded in May 2020 to better reflect its expanded mission and strategic focus. Headquartered in New York, New York, the company continues to push the boundaries of therapeutic development with its promising investigational therapies.
|
